No Data
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3
Innovent Enters Into Exclusive Global License Agreement With Roche for Novel DLL3 Antibody Drug Conjugate
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Roche CEO Reassures No Job Cuts Despite Challenges: Report
Novartis Says New Drug Helps Children With Rare Spinal Condition
No Data
Tatae2023 : sorry to disappoint you Ryan, we part of a disolved, insolvent company and non trading. LumiraDx UK is a different division which was rented to Roche to make some money for them... LumiraDx UK never been trading ...
Ryand83 OP Tatae2023 : we will either transfer or be paid out. There was no investing for retail into the UK Subsidiary. Still undisclosed, save that shill talk you let those
s get in your head.
Ryand83 OP Ryand83 OP : remember liquidation didn't officially start until February 1st we still have time
Tatae2023 : ok, I can't do anything , money gone for long, I won't ask to clear them out from my broker, let my shares there till whatever...🫡